Savara Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
4/18/2013 9:52:46 AM
More...
|
Savara Lands $7.4 Million to Close a $16 Million Series B Round
3/21/2013 8:33:58 AM
More...
|
Savara Announces Formation of Clinical Advisory Board
2/26/2013 9:40:37 AM
More...
|
Savara' AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
11/13/2012 10:19:15 AM
More...
|
Keiretsu Forum Members Make Substantial Bet on Savara
7/17/2012 10:44:25 AM
More...
|
Savara Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
6/12/2012 11:08:31 AM
More...
|
Savara Raises $8.6 Million in Series B Financing Round
6/12/2012 7:50:23 AM
More...
|
Savara's AeroVanc for Cystic Fibrosis Patients Achieves Positive Results in Phase I Clinical Trial
4/26/2012 11:55:48 AM
More...
|
Savara Joins SAFE-BioPharma, LLC Association
11/21/2011 8:54:44 AM
More...
|
Savara Announces Appointment of Pharmaceutical Veteran to Board of Directors
11/8/2010 6:41:26 AM
More...
|
|